Dynavax names new CEO
This article was originally published in Scrip
Dynavax Technologies, a biopharmaceutical company developing products to prevent and treat infectious and inflammatory diseases, has appointed Eddie Gray chief executive officer and a member of its board of directors, effective 1 May 2013. Before joining Berkeley, California-based Dynavax, Mr Gray served as president of pharmaceuticals Europe at big pharma GlaxoSmithKline. He succeeds Dr Dino Dina as CEO of the Dynavax. Dr Dina will remain a consultant to the firm for the transitional period and plans to continue to serve on the company's board. Additionally, Dr Tyler Martin, president, is departing from Dynavax on 31 May 2013.
You may also be interested in...
Diversity in all forms is critical to innovation in health care, says AstraZeneca’s chief medical officer, Ann Taylor. In an exclusive interview, she talks about the company’s work in mentoring and education, and why tackling issues around diversity and inclusion must be driven by the C-suite alongside community initiatives.
A selection of articles you might have missed from October 2020, including exclusive interviews with industry leaders and a deeper dive into the Femtech market.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.